Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Mar;19(3):275-81.
doi: 10.1097/cad.0b013e3282f3fd2e.

Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients

Affiliations
Comparative Study

Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients

Zyting Chu et al. Anticancer Drugs. 2008 Mar.

Abstract

The formulation excipient Cremophor EL (CrEL) is known to limit the absorption of oral paclitaxel given together with cyclosporin A. We hypothesized that the use of oral Genetaxyl, a paclitaxel formulation containing only 20% CrEL would have an improved oral bioavailability. Cohorts of six patients were treated with oral Genetaxyl at a dose of 60, 120, or 180 mg/m2 and 10 mg/kg of oral cyclosporin A in cycle 1. In cycle 2, patients received intravenous (i.v.) Genetaxyl (175 mg/m2, 3-h infusion). Three additional patients received one dose of generic i.v. paclitaxel (Genaxol, containing 50% CrEL; 175mg/m2, 3-h infusion). The median area under the plasma concentration-time curve (AUC) and peak concentration of total paclitaxel following i.v. Genetaxyl were lower than those for i.v. Genaxol, as a result of significantly increased clearance (P = 0.017), and the AUC ratio for unbound to total paclitaxel for i.v. Genetaxyl was about two times higher than that for i.v. Genaxol (P = 0.0077). After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses. The corresponding median values for the apparent bioavailability of oral Genetaxyl were similar when compared with i.v. Genetaxyl, when calculated either on the basis of data for total paclitaxel (30.1%) or unbound paclitaxel (30.6%).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Plasma concentration-time profile of total and unbound paclitaxel following a 3-hour i.v. infusion of Genaxol or Genetaxyl at dose of 175 mg/m2 . Data are shown as mean values (symbols) with standard deviation (error bars).
Fig. 2
Fig. 2
Plasma concentration-time profile of total and unbound paclitaxel after oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2. Data are shown as mean values (symbols) with standard deviation (error bars).

Similar articles

Cited by

References

    1. Estevez LG, Munoz M, Alvarez I, Fernandez Y, Garcia-Mata J, Ruiz-Borrego M, et al. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treat Rev. 2007;33:474–483. - PubMed
    1. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Taxanes as first-line treatment for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer. 2005;50:355–374. - PubMed
    1. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33(2 Supl 6):S3–S11. - PubMed
    1. Hait WN, Rubin E, Goodin S. Tubulin-targeting agents. Cancer Chemother Biol Response Modif. 2003;21:41–67. - PubMed
    1. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94:2031–2035. - PMC - PubMed

Publication types

MeSH terms